ImmunoPrecise Antibodies Ltd. Files 6-K with Press Release
Ticker: HYFT · Form: 6-K · Filed: Jul 15, 2024 · CIK: 1715925
| Field | Detail |
|---|---|
| Company | Immunoprecise Antibodies LTD. (HYFT) |
| Form Type | 6-K |
| Filed Date | Jul 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release, regulatory-update
TL;DR
IPA files 6-K with July 15 press release - check for updates.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on July 15, 2024, to report a press release dated July 15, 2024. The filing indicates the company is a foreign private issuer and will file annual reports under Form 20-F. The press release itself is included as Exhibit 99.1.
Why It Matters
This filing provides an update from ImmunoPrecise Antibodies Ltd. to the SEC, including a press release which may contain important business or financial information for investors.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to submit a press release, with no immediate indication of significant new risks or material adverse events.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Filer of the report
- Kristin Taylor (person) — Signed the report on behalf of the company
- July 15, 2024 (date) — Date of the press release and filing
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report a press release dated July 15, 2024, as required for foreign private issuers.
What exhibit is included with this filing?
Exhibit 99.1, a Press Release dated July 15, 2024, is included with this filing.
Which form does ImmunoPrecise Antibodies Ltd. use for its annual reports?
ImmunoPrecise Antibodies Ltd. indicates it files annual reports under cover of Form 20-F.
Who signed the report on behalf of ImmunoPrecise Antibodies Ltd.?
The report was signed by Kristin Taylor, who holds the title of [Title not fully specified in provided text, but implied to be authorized].
What is the filing date of this report?
This report was filed on July 15, 2024.
Filing Stats: 143 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2024-07-15 08:32:43
Filing Documents
- press_release_july_15_20.htm (6-K) — 21KB
- ipa-ex99_1.htm (EX-99.1) — 14KB
- 0000950170-24-083398.txt ( ) — 36KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: July 15, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer